For healthcare professionals who require more information about shortages, please contact MSD Ireland on +353 1 299 8700.
If you are a patient seeking information on how shortages may affect your treatment, we recommend that you consult your doctor.
For more information about our products, please call our medical information line via our switchboard on +353 1 299 8700.
In 2011 the European Commission passed the Falsified Medicines Directive (FMD), requiring the implementation of safety features to avoid falsified medicines being dispensed to patients. This came into effect in February 2019 and all prescription medicines must now be scanned by the pharmacist at the point of dispensing.
Pharmacists can report a suspected Falsified Medicine by phoning MSD Ireland at 01 299 8700.
If you have any additional queries or require any further information please contact the Irish Medicines Verification Organisation directly on their website at imvo.ie
From March 2019, Keytruda (pembrolizumab) will be supplied by MSD exclusively in the form of 100 mg vial (25 mg/mL concentrate for solution for infusion) and availability of the 50 mg vial as lyophilised powder (50 mg powder for concentrate for solution for infusion) will begin to cease. At that time, remaining stocks of the 50 mg vial of Keytruda (pembrolizumab) powder for concentrate for solution for infusion may continue to be used until the stock is finished.